Procollagen type I amino-terminal propeptide: Pediatric reference data and relationship with procollagen type I carboxyl-terminal propeptide

Clinical Chemistry

Volumn 50, Issue 11, 2004, Pages 2173-2176

  Crofton, Patricia M ^a,b   Evans, Nancy ^b   Taylor, Mervyn R H ^c,d   Holland, Celia V ^d  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c ADELAIDE AND MEATH HOSPITAL   (Ireland)

^d TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; PROCOLLAGEN TYPE 1 CARBOXYL TERMINAL PROPEPTIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; HUMAN; MAJOR CLINICAL STUDY; RADIOIMMUNOASSAY;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; PEPTIDE FRAGMENTS; PROCOLLAGEN; REFERENCE VALUES; SEX FACTORS;

EID: 7044286279     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.039958     Document Type: Article

References (21)

1. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 1996;42:947-54.
2. Smedsrød B, Melkko J, Risteli L, Risteli J. Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 1990;271:345-50.
3. Melkko J, Hellevik T, Risteli L, Risteli J, Smedsrød B. The amino-terminal propeptide of type I procollagen is a physiological ligand for the scavenger receptor of the endothelial cells of the liver. J Exp Med 1994;179:405-12.
4. Risteli L, Risteli J. Biochemical markers of bone metabolism [Review]. Ann Med 1993;25:385-93.
5. Tähtelä R, Turpeinen M, Sorva R, Karonen S-L. The aminoterminal propeptide of type I procollagen: evaluation of a commercial radioimmunoassay kit and values in healthy subjects. Clin Biochem 1997;30:35-40.
6. Hannon R, Blumsohn A, Naylor K, Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 1998;13:1124-33.
7. Alvarez L, Peris P, Pons F, Guanabens N, Herranz R, Monegal A, et al. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity. Arthritis Rheum 1997;40:461-8.
8. Dominguez Cabrera C, Sosa Henriquez M, Traba ML, Alvarez Villafane E, de la Piedra C. Biochemical markers of bone formation in the study of postmenopausal osteoporosis. Osteoporos Int 1998;8:147-51.
9. Saarto T, Blomqvist C, Risteli J, Risteli L, Sarna S, Elomaa I. Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients. Br J Cancer 1998;78:240-5.
10. Scariano JK, Glew RH, Bou-Serhal CE, Clemens JD, Garry PJ, Baumgartner RN. Serum levels of cross-linked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women. Bone 1998;23:471-7.
11. Scariano JK, Garry PJ, Montoya GD, Duran-Valdez E, Baumgartner RN. Diagnostic efficacy of serum cross-linked N-telopeptide (NTx) and aminoterminal procollagen extension propeptide (PINP) measurements for identifying elderly women with decreased bone mineral density. Scand J Clin Lab Invest 2002;62:237-43.
12. Evio S, Tiitinen A, Laitinen K, Ylikorkala O, Valimaki MJ. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. J Clin Endocrinol Metab 2004;89:626-31.
13. Rauch F, Schönau E. Markers of bone metabolism-use in pediatrics [Review]. Clin Lab 1997;43:743-52.
14. Crofton PM, Kelnar CJH. Bone and collagen markers in paediatric practice [Review]. Int J Clin Pract 1998;52:557-65.
15. Crofton PM, Ahmed SF, Wade JC, Stephen R, Elmlinger MW, Ranke MB, et al. Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia. J Clin Endocrinol Metab 1998;83:3121-9.
16. Holland CV, O'Lorcain P, Taylor MRH, Kelly A. Sero-epidemiology of toxocariasis in school children. Parasitology 1995;110:535-45.
17. Crofton PM, Wade JC, Taylor MR, Holland CV. Serum concentrations of carboxyl-terminal propeptide of type I procollagen, amino-terminal propeptide of type III procollagen, cross-linked carboxyl-terminal telopeptide of type I collagen, and their interrelationships in schoolchildren. Clin Chem 1997;43:1577-81.
18. Crofton PM, Ahmed SF, Wade JC, Elmlinger MW, Ranke MB, Kelnar CJH, et al Bone turnover and growth during and after continuing chemotherapy in children with acute lymphoblastic leukemia. Pediatr Res 2000;48:490-6.
19. Trivedi P, Risteli J, Risteli L, Hindmarsh PC, Brook CG, Mowat AP. Serum concentrations of the type I and III procollagen propeptides as biochemical markers of growth velocity in healthy infants and children with growth disorders. Pediatr Res 1991;30:276-80.
20. Sorva R, Anttila R, Siimes MA, Sorva A, Tähtelä R, Turpeinen M. Serum markers of collagen metabolism and serum osteocalcin in relation to pubertal development in 57 boys at 14 years of age. Pediatr Res 1997;42:528-32.
21. Van der Sluis M, Hop WC, van Leeuwen JPTM, Pols HAP, de Muinck Keizer-Schrama SMPF. A cross-sectional study on biochemical parameters of bone turnover and vitamin D metabolites in healthy Dutch children and young adults. Horm Res 2002;57:170-9.